- Contractors
- Myelo Therapeutics Gmbh
Myelo Therapeutics Gmbh
Federal contractor · Research and Development in Biotechnology (except Nanobiotechnology)
Myelo Therapeutics Gmbh has 1 federal contract of $100,000 or more active since October 2023, with $6.73M obligated, from 1 agency. None is running now.
- Contracts
- 1 since FY2024$6,728,096 obligated, contracts of $100,000 or more
- Running now
- None
- Biggest customer
- National Institutes of Health$6.73M on 1 contract
- Main industry
- Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714
- UEI
- G1LNCHNLYXF6Unique entity ID in SAM.gov
- Source
- USAspending.govUpdated Nov 17, 2026, 7:02 PM UTC
Running contracts
No contract of $100,000 or more is running now.
Who they work for
| Agency | Amount | Share |
|---|---|---|
| National Institutes of Health1 contract | $6,728,096 |
What they sell
| Industry | Amount | Share |
|---|---|---|
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 · 1 contract | $6,728,096 |
Source: USAspending.gov, prime contracts of $100,000 or more with an action since October 1, 2023. Department of Defense contracts appear there about 90 days after award. Other contracts ending soon at National Institutes of Health: see the list.
Get new notices like Myelo Therapeutics Gmbh's work
New contract opportunities under NAICS 541714, research and development in biotechnology (except nanobiotechnology), the morning they appear. Free while in beta.
Free. We use your email only for these alerts and never share it. Privacy